Immunotherapies in the treatment sequence of head and neck cancer

被引:0
作者
Mueller-Richter, Urs D. A. [1 ,3 ]
Brands, Roman C. [2 ]
Hartmann, Stefan [2 ]
机构
[1] Bayer Zentrum Krebsforsch BZKF, Comprehens Canc Ctr Mainfranken CCC MF, Klin Mund Kiefer & Plast Gesichtschirurg, NCT WERA, Wurzburg, Germany
[2] Univ Klinikum Wurzburg, Klin Mund Kiefer & Plast Gesichtschirurg, Wurzburg, Germany
[3] Bayer Zentrum Krebsforsch BZKF, Comprehens Canc Ctr Mainfranken CCC MF, Klin Mund Kiefer & Plast Gesichtschirurg, NCT WERA, Pleicherwall 2, D-97070 Wurzburg, Germany
来源
MKG-CHIRURGIE | 2023年
关键词
Oral squamous cell carcinomas; Immunotherapy; Checkpoint inhibitors; Radiotherapy; Salvage therapy; SQUAMOUS-CELL CARCINOMA; RECURRENT; NIVOLUMAB;
D O I
10.1007/s12285-023-00440-2
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Drug therapy of head and neck cancer has changed dramatically during the past 5 years due to the approval of immunotherapy in the palliative setting. With nivolumab and pembrolizumab firmly established in second- and first-line recurrent or metastatic situations, various completed or ongoing clinical trials focus on the adjuvant or neoadjuvant setting. Currently available results show that addition of a checkpoint inhibitor to definitive radiochemotherapy fails to elicit an advantage. The currently running ADRISK trial assessing pembrolizumab in the context of adjuvant radiochemotherapy is still recruiting and results cannot be expected in the near future. Currently available early data on the use of a checkpoint inhibitor after salvage surgery appear promising, although clear treatment recommendations cannot be derived at present. It is, however, in principle possible for clinicians to submit a proposal for off-label use to the provider on the basis of these trials in high-risk situations. In the authors' opinion, the field of neoadjuvant immunotherapy is by far the most interesting. On the one hand, large phase III studies that challenge the established treatment standard are currently open. On the other, in the case of positive results, a large number of patients will be affected by changes in the treatment sequence. The mentioned trials address locally advanced stages, as suffered by the majority of patients at initial diagnosis. Application of immunotherapy with subsequent biopsy continues to be an excellent tool to guide patient-specific neoadjuvant or maintenance therapy.
引用
收藏
页数:7
相关论文
共 8 条
[1]   Neoadjuvant immunotherapy prior to surgery for mucosal head and neck squamous cell carcinoma: Systematic review [J].
Amin, Neha ;
Maroun, Christopher A. ;
El Asmar, Margueritta ;
Alkhatib, Hosam H. ;
Guller, Meytal ;
Herberg, Matthew E. ;
Zhu, Gangcai ;
Seiwert, Tanguy Y. ;
Pardoll, Drew ;
Eisele, David W. ;
Fakhry, Carole ;
Gourin, Christine G. ;
Mandal, Rajarsi .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2022, 44 (02) :562-571
[2]   Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [J].
Burtness, Barbara ;
Harrington, Kevin J. ;
Greil, Richard ;
Soulieres, Denis ;
Tahara, Makoto ;
de Castro, Gilberto, Jr. ;
Psyrri, Amanda ;
Baste, Neus ;
Neupane, Prakash ;
Bratland, Ase ;
Fuereder, Thorsten ;
Hughes, Brett G. M. ;
Mesia, Ricard ;
Ngamphaiboon, Nuttapong ;
Rordorf, Tamara ;
Ishak, Wan Zamaniah Wan ;
Hong, Ruey-Long ;
Mendoza, Rene Gonzalez ;
Roy, Ananya ;
Zhang, Yayan ;
Gumuscu, Burak ;
Cheng, Jonathan D. ;
Jin, Fan ;
Rischin, Danny .
LANCET, 2019, 394 (10212) :1915-1928
[3]   Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [J].
Ferris, R. L. ;
Blumenschein, G., Jr. ;
Fayette, J. ;
Guigay, J. ;
Colevas, A. D. ;
Licitra, L. ;
Harrington, K. ;
Kasper, S. ;
Vokes, E. E. ;
Even, C. ;
Worden, F. ;
Saba, N. F. ;
Iglesias Docampo, L. C. ;
Haddad, R. ;
Rordorf, T. ;
Kiyota, N. ;
Tahara, M. ;
Monga, M. ;
Lynch, M. ;
Geese, W. J. ;
Kopit, J. ;
Shaw, J. W. ;
Gillison, M. L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1856-1867
[4]   Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial [J].
Ferris, Robert L. ;
Spanos, William C. ;
Leidner, Rom ;
Goncalves, Anthony ;
Martens, Uwe M. ;
Kyi, Chrisann ;
Sharfman, William ;
Chung, Christine H. ;
Devriese, Lot A. ;
Gauthier, Helene ;
Chiosea, Simon, I ;
Vujanovic, Lazar ;
Taube, Janis M. ;
Stein, Julie E. ;
Li, Jun ;
Li, Bin ;
Chen, Tian ;
Barrows, Adam ;
Topalian, Suzanne L. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (06)
[5]   High-risk pathological features at the time of salvage surgery predict poor survival after definitive therapy in patients with head and neck squamous cell carcinoma [J].
Haque, Sulsal ;
Karivedu, Vidhya ;
Riaz, Muhammed K. ;
Choi, David ;
Roof, Logan ;
Hassan, Sarah Z. ;
Zhu, Zheng ;
Jandarov, Roman ;
Takiar, Vinita ;
Tang, Alice ;
Wise-Draper, Trisha .
ORAL ONCOLOGY, 2019, 88 :9-15
[6]  
Leddon JL, 2022, CLIN CANCER RES, V28, P3464, DOI [10.1158/1078-0432.CCR-21-4554, DOI 10.1158/1078-0432.CCR-21-4554]
[7]   Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial [J].
Uppaluri, Ravindra ;
Campbell, Katie M. ;
Egloff, Ann Marie ;
Zolkind, Paul ;
Skidmore, Zachary L. ;
Nussenbaum, Brian ;
Paniello, Randal C. ;
Rich, Jason T. ;
Jackson, Ryan ;
Pipkorn, Patrik ;
Michel, Loren S. ;
Ley, Jessica ;
Oppelt, Peter ;
Dunn, Gavin P. ;
Barnell, Erica K. ;
Spies, Nicholas C. ;
Lin, Tianxiang ;
Li, Tiantian ;
Mulder, David T. ;
Hanna, Youstina ;
Cirlan, Iulia ;
Pugh, Trevor J. ;
Mudianto, Tenny ;
Riley, Rachel ;
Zhou, Liye ;
Jo, Vickie Y. ;
Stachler, Matthew D. ;
Hanna, Glenn J. ;
Kass, Jason ;
Haddad, Robert ;
Schoenfeld, Jonathan D. ;
Gjini, Evisa ;
Lako, Ana ;
Thorstad, Wade ;
Gay, Hiram A. ;
Daly, Mackenzie ;
Rodig, Scott J. ;
Hagemann, Ian S. ;
Kallogjeri, Dorina ;
Piccirillo, Jay F. ;
Chernock, Rebecca D. ;
Griffith, Malachi ;
Griffith, Obi L. ;
Adkins, Douglas R. .
CLINICAL CANCER RESEARCH, 2020, 26 (19) :5140-5152
[8]  
Yu Yao, 2021, Oncotarget, V12, P2223, DOI 10.18632/oncotarget.27987